Your browser is no longer supported. Please, upgrade your browser.
Settings
KERX Keryx Biopharmaceuticals, Inc. daily Stock Chart
KERX [NASD]
Keryx Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own0.80% Shs Outstand108.47M Perf Week5.54%
Market Cap702.89M Forward P/E- EPS next Y-0.23 Insider Trans-6.50% Shs Float104.23M Perf Month9.83%
Income-143.10M PEG- EPS next Q-0.18 Inst Own64.80% Short Float21.06% Perf Quarter32.79%
Sales37.00M P/S19.00 EPS this Y-28.40% Inst Trans1.25% Short Ratio15.40 Perf Half Y4.68%
Book/sh-0.21 P/B- EPS next Y66.70% ROA-88.20% Target Price7.71 Perf Year9.64%
Cash/sh0.84 P/C7.73 EPS next 5Y- ROE- 52W Range4.03 - 7.80 Perf YTD10.58%
Dividend- P/FCF- EPS past 5Y-29.30% ROI-103.90% 52W High-17.50% Beta5.16
Dividend %- Quick Ratio4.80 Sales past 5Y44.90% Gross Margin-18.90% 52W Low59.61% ATR0.23
Employees193 Current Ratio5.40 Sales Q/Q73.50% Oper. Margin- RSI (14)55.16 Volatility3.30% 3.89%
OptionableYes Debt/Eq- EPS Q/Q44.60% Profit Margin- Rel Volume0.40 Prev Close6.48
ShortableYes LT Debt/Eq- EarningsMay 04 BMO Payout- Avg Volume1.42M Price6.43
Recom2.40 SMA201.74% SMA507.15% SMA20018.82% Volume557,853 Change-0.69%
May-08-17Reiterated Maxim Group Buy $7 → $9
Jan-11-17Upgrade Citigroup Sell → Neutral
Nov-09-16Upgrade Maxim Group Hold → Buy $7
Aug-02-16Downgrade Stifel Buy → Hold
Aug-02-16Downgrade FBR Capital Outperform → Mkt Perform $16 → $7
Aug-02-16Downgrade Brean Capital Buy → Hold
Aug-01-16Downgrade Maxim Group Buy → Hold
Jul-08-16Reiterated Maxim Group Buy $7 → $9
Mar-30-16Reiterated FBR Capital Outperform $10 → $13
Feb-29-16Upgrade FBR Capital Mkt Perform → Outperform $10
Feb-26-16Upgrade Raymond James Mkt Perform → Outperform
Feb-26-16Reiterated Stifel Buy $10 → $9
Feb-26-16Downgrade JP Morgan Overweight → Neutral
Feb-25-16Reiterated Maxim Group Buy $11 → $5
Oct-05-15Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-09-15Initiated Raymond James Mkt Perform
Sep-03-15Initiated Citigroup Sell
Aug-13-15Initiated Morgan Stanley Underweight $3
Aug-11-15Initiated FBR Capital Mkt Perform $10
Aug-10-15Downgrade ROTH Capital Buy → Neutral $11 → $6
May-22-17 01:50PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 22, 2017 Capital Cube
May-19-17 08:00AM  Top 4 Pharmaceutical Stocks for 2017 Investopedia
May-11-17 04:59PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 11, 2017 Capital Cube
May-10-17 08:55PM  Edited Transcript of KERX earnings conference call or presentation 4-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-09-17 11:10AM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 Capital Cube
May-05-17 10:37AM  Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat Zacks +5.35%
08:00AM  Today's Research Reports on Biotech Stocks to Watch: BioCryst Pharmaceuticals and Keryx Biopharmaceuticals Accesswire
May-04-17 07:57AM  Keryx Biopharma reports 1Q loss Associated Press +6.56%
07:41AM  Keryx (KERX) Posts Wider-than-Expected Q1 Loss, Sales Beat Zacks
07:05AM  Investor Network: Keryx Biopharmaceuticals, Inc. to Host Earnings Call Accesswire
07:02AM  Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results GlobeNewswire
May-01-17 07:40AM  Keryx Announces that Auryxia® (Ferric Citrate) is Now on Formulary at All Major Medicare Part D Plans GlobeNewswire
Apr-28-17 06:07PM  What to Expect from Keryx (KERX) Stock This Earnings Season? Zacks
Apr-18-17 08:35AM  Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017 GlobeNewswire
Apr-10-17 09:35AM  Lawsuit for Investors in NASDAQ: KERX Shares Against Keryx Biopharmaceuticals Announced by Shareholders Foundation Accesswire
Apr-07-17 04:59PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : April 7, 2017 Capital Cube
09:02AM  Here's Why Keryx Biopharmaceuticals Jumped 27.3% in March Motley Fool
Apr-04-17 07:00AM  Why Is Keryx (KERX) Up 27.4% Since the Last Earnings Report? Zacks
07:00AM  Why Is Keryx (KERX) Up 27.4% Since the Last Earnings Report?
Mar-22-17 05:27PM  Keryx's Auryxia Added to Largest Medicare Part D Plan Zacks
05:27PM  Keryx's Auryxia Added to Largest Medicare Part D Plan
Mar-21-17 09:30AM  Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation Accesswire -9.70%
Mar-20-17 07:30AM  Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Plan Formularies GlobeNewswire +7.89%
Mar-16-17 06:12PM  Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat Zacks
06:12PM  Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat
Mar-09-17 08:15AM  Blog Coverage Keryx Biopharma Announced FDA Review Approval for Auryxia(R) Tablets Accesswire
Mar-08-17 03:51PM  3 Top Stocks Under $5 Motley Fool
03:51PM  3 Top Stocks Under $5 at Motley Fool
07:30AM  Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Auryxia® (ferric citrate) Tablets GlobeNewswire
Mar-07-17 01:55PM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube
01:55PM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
01:04PM  KERYX BIOPHARMACEUTICALS INC Financials
11:06AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Keryx Biopharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Mar-02-17 04:51PM  Keryx (KERX) Q4 Loss Wider than Expected, Revenues Beat
Mar-01-17 06:40PM  Edited Transcript of KERX earnings conference call or presentation 1-Mar-17 1:00pm GMT
09:22AM  Keryx (KERX) Posts Wider-than-Expected Loss in Q4
08:00AM  Keryx Biopharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
07:29AM  Keryx Biopharma reports 4Q loss
07:07AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q4 2016 Keryx Biopharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 08:51AM  Should You Sell Keryx Biopharmaceuticals (KERX) Before Earnings?
07:24AM  Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
07:17AM  Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More
Feb-27-17 08:21AM  Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?
Feb-24-17 05:06PM  Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
Feb-23-17 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentations at Two Investor Conferences in March 2017 GlobeNewswire
Feb-16-17 09:15AM  Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017 GlobeNewswire -7.97%
Feb-08-17 09:01AM  Keryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' 2017 Global Healthcare Conference on February 22, 2017 GlobeNewswire
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on MannKind and Keryx Accesswire
Jan-23-17 12:02PM  Keryx Biopharmaceuticals, Inc. Value Analysis (NASDAQ:KERX) : January 23, 2017
Jan-20-17 08:31AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : January 20, 2017
Jan-13-17 06:13PM  Keryx Releases Auryxia Data for Iron Deficiency Anemia
Jan-12-17 09:54AM  Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology GlobeNewswire
Jan-11-17 06:24AM  Keryx Biopharma upgraded by Citigroup
Jan-09-17 08:32AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors o
Jan-08-17 06:00PM  Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-17 02:46PM  Robbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a Recently Filed Lawsuit Business Wire
Jan-03-17 02:24PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : January 3, 2017
Dec-30-16 08:35AM  Implied Volatility Surging for Keryx (KERX) Stock Options
Dec-24-16 09:51AM  3 Companies Whose Revenue Could Double in 2017 at Motley Fool
Dec-22-16 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgans 35th Annual Healthcare Conference on January 11, 2017 GlobeNewswire
Dec-19-16 11:48AM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : December 19, 2016
Dec-15-16 02:01PM  Favorite Healthcare Stocks of Billionaire Seth Klarmans Baupost Group at Insider Monkey
Dec-11-16 04:48AM  Do Hedge Funds Love Keryx Biopharmaceuticals Inc (KERX)? at Insider Monkey
Dec-06-16 03:54PM  This Is Why Keryx Biopharmaceuticals Surged 28% in November at Motley Fool
Dec-05-16 12:18PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : December 5, 2016
Nov-28-16 09:47AM  3 Biotech Investing Tips That Could Earn You Thousands at Motley Fool
Nov-23-16 01:08PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : November 23, 2016
Nov-21-16 10:15AM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
Nov-18-16 10:31AM  Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASNs Kidney Week GlobeNewswire
08:45AM  Keryx (KERX) Stock Up on Positive Phase III Auryxia Data
Nov-17-16 10:31AM  Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) GlobeNewswire
Nov-11-16 03:41PM  Here's Why Keryx Biopharmaceuticals Soared As Much As 13.1% Today at Motley Fool +13.70%
Nov-10-16 08:27AM  Keryx (KERX) Q3 Loss Wider than Expected, Restores Supply
05:40AM  FDA action helps Keryx move past drug supply snafu at bizjournals.com
Nov-09-16 04:45PM  Why Keryx Biopharmaceuticals Stock Jumped Today at Motley Fool +13.36%
04:39PM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events
01:31PM  Edited Transcript of KERX earnings conference call or presentation 9-Nov-16 1:00pm GMT
12:57PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : November 9, 2016
10:58AM  Here's Why Keryx Biopharmaceuticals Fell 18% in October at Motley Fool
10:42AM  Keryx Biopharmaceuticals Announces U.S. FDA Approval of Second Contract Manufacturer for Auryxia® (ferric citrate) GlobeNewswire
09:16AM  Keryx (KERX) Posts Wider-than-Expected Loss in Q3
08:00AM  Keryx Biopharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
07:42AM  Keryx Biopharma reports 3Q loss
07:07AM  Q3 2016 Keryx Biopharmaceuticals Inc Earnings Release - Before Market Open
07:01AM  Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-16 07:53AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : November 8, 2016
Nov-03-16 08:31AM  Keryx Biopharmaceuticals to Webcast its Presentation at Stifels 2016 Healthcare Conference on November 15 GlobeNewswire -5.88%
Nov-01-16 09:15AM  Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2016 Financial Results on Wednesday, November 9, 2016 GlobeNewswire
07:44AM  Keryx (KERX) Q3 Earnings Preview: Stock to Beat Estimates?
Oct-20-16 01:32PM  Here Are Two Dates To Keep An Eye On In Biotech Across The Next Two Weeks at Insider Monkey +5.45%
Oct-19-16 12:35PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : October 19, 2016
Oct-18-16 08:33AM  Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : October 18, 2016
Oct-17-16 05:28PM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure -6.84%
Oct-14-16 10:13AM  Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting GlobeNewswire
Oct-12-16 05:35PM  Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday -8.49%
Oct-09-16 08:28AM  What's Behind Keryx Biopharmaceuticals' 28.6% Jump in September? at Motley Fool
Oct-04-16 10:03AM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : October 4, 2016
Oct-01-16 10:06AM  MONDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm Accesswire
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has a license agreement with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Madison GregPresident and CEOMay 01Sale5.974,12224,608378,678May 03 04:06 PM
Adams BrianGeneral Counsel and SecretaryMay 01Sale5.971,4418,603138,136May 03 04:05 PM
Holmes Scott AChief Financial OfficerMay 01Sale5.971,4418,603144,963May 03 04:05 PM
Neylan John F.Chief Medical OfficerMay 01Sale5.971,4418,603129,244May 03 04:05 PM
Holmes Scott AChief Financial OfficerApr 28Sale5.891,2197,180146,404May 01 04:05 PM
Neylan John F.Chief Medical OfficerApr 24Sale5.731,2096,928130,685Apr 26 04:05 PM
Adams BrianGeneral Counsel and SecretaryApr 17Sale5.751,0906,268139,577Apr 18 04:05 PM
Adams BrianGeneral Counsel and SecretaryApr 05Sale5.806423,724140,667Apr 06 04:05 PM
Madison GregPresident and CEOApr 05Sale5.809115,284382,800Apr 06 04:05 PM
Madison GregPresident and CEOFeb 09Sale5.471,6118,812233,711Feb 13 04:18 PM
Madison GregPresident and CEOJan 30Sale4.6518,24884,853235,322Jan 31 04:05 PM
Holmes Scott AChief Financial OfficerJan 30Sale4.658,44739,27998,873Jan 31 04:05 PM
Neylan John F.Chief Medical OfficerJan 30Sale4.656,98432,47683,144Jan 31 04:05 PM
Adams BrianGeneral Counsel and SecretaryJan 30Sale4.656,98432,47692,559Jan 31 04:05 PM
Neylan John F.Chief Medical OfficerJan 23Sale5.391,4287,69790,128Jan 25 04:06 PM
Adams BrianVP and General CounselJan 17Sale6.241,2657,89499,543Jan 18 04:05 PM
Adams BrianVP and General CounselJan 05Sale6.167594,675100,808Jan 06 04:06 PM
Madison GregPresident and CEOJan 05Sale6.161,0776,634253,570Jan 06 04:05 PM
Madison GregPresident and CEONov 09Sale4.991,5597,779254,647Nov 14 04:06 PM
Holmes Scott AChief Financial OfficerOct 28Sale4.441,2375,492107,320Oct 31 04:07 PM
Neylan John F.Chief Medical OfficerOct 24Sale4.721,2115,71691,556Oct 25 04:05 PM
Adams BrianVP and General CounselOct 17Sale4.861,1065,375101,567Oct 18 04:05 PM
Adams BrianVP and General CounselOct 05Sale5.386473,481102,673Oct 06 04:05 PM
Madison GregPresident and CEOOct 05Sale5.389174,933256,206Oct 06 04:05 PM
Madison GregPresident and CEOAug 09Sale4.221,6226,845257,123Aug 11 05:44 PM
Madison GregPresident and CEOAug 09Sale4.221,6226,845257,123Aug 11 05:45 PM
Holmes Scott AChief Financial OfficerJul 29Sale7.364,93536,322108,557Aug 02 05:00 PM
Neylan John F.Chief Medical OfficerJul 25Sale7.431,2179,04292,767Jul 27 05:00 PM
Adams BrianVP and General CounselJul 15Sale7.011,0837,592103,320Jul 18 07:10 PM
Madison GregPresident and CEOJul 05Sale6.669366,234258,745Jul 06 04:17 PM
Adams BrianVP and General CounselJul 05Sale6.666604,396104,403Jul 06 04:18 PM